Search Results 21-30 of 16654 for ������������KA���:ZA31���24������ ���������������������������������

  1. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...

  2. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment - Mayo Clinic

    ... 24 hours[hrs]); OR - IgA, IgM, IgD, or IgE multiple myeloma (serum M-protein level >= 0.2 g/dL or urine M-protein level >= 200 mg/24 hrs); OR - Light chain ...

  3. Health Topics - Mayo Clinic News Network

    If you're planning a Labor Day gathering outdoors, remember that food safety is important for everybody, but it is especially important if you're expecting.

  4. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors - Mayo Clinic

    PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a ...

  5. Holter monitor - Mayo Clinic

    24, 2022. AskMayoExpert. Ambulatory heart rhythm monitoring. Mayo Clinic; 2021. Medical review (expert opinion). Mayo Clinic. Dec. 5, 2018. Rajakariar K, et al.

  6. Clinical trials - Oncology (Medical)

    Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients ...

  7. OHF Patient Registry - Mayo Clinic

    Rochester, Minnesota: 24-007676. About this study. The purpose of this study is that the Oxalosis and Hyperoxaluria Foundation (OHF) Registry in collaboration ...

  8. https://www.mayoclinic.org/chinese_condition_consolidated_concepts.xml

    ... 24-06:00</lastmod><xhtml:link rel="alternate" hreflang="ar" href="https://www.mayoclinic.org/ar/diseases-conditions/spinal-cord-tumor/symptoms-causes/syc ...

  9. A Study Evaluating The Safety And Efficacy Of Inhaled AP01 In Participants With Progressive Pulmonary Fibrosis - Mayo Clinic

    Rochester, Minnesota: 24-005197; Scottsdale/Phoenix, Arizona: 24-005197. NCT ID: NCT06329401. Sponsor Protocol Number: AP01. About this study. A randomized ...

  10. Publications - Cady K. Block, Ph.D., ABPP-CN, L.P. - Mayo Clinic

    2024 Oct 21; 1-24 [Epub ahead of print] View ... 2024 Jun; 155:109669 Epub 2024 Apr 24. View PubMed ... KA, Del Bene VA. Diverse experiences and ...